AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The Australian Securities Exchange (ASX) has seen notable movements in the share prices of some key companies this year. Two ASX value stocks, ResMed CDI and Pilbara Minerals Ltd, have attracted significant attention from investors. Here's an update on their recent performance and what sets them apart.
ResMed CDI (ASX:RMD)
ResMed CDI, founded in 1989 by Peter Farrell, has experienced a remarkable 34.6% increase in its share price since the beginning of 2024. Though the company originated in Australia, it is now headquartered in San Diego, California. ResMed is renowned for its medical equipment, particularly its cloud-connected continuous positive airway pressure (CPAP) machines used to treat obstructive sleep apnea (OSA).
The company's operations span globally, with more than 10,000 employees and a presence in over 140 countries. ResMed operates through two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care unit focuses on providing CPAP machines and other equipment for patients with sleep apnea and respiratory conditions. The SaaS unit offers software solutions to support home medical equipment, contributing to improved out-of-hospital care.
ResMed leverages its digital health network and cloud-connected devices to offer valuable insights, enhance treatment outcomes, and reduce overall healthcare costs. This innovative approach has been a key factor in the company’s recent stock price growth.
Pilbara Minerals Ltd (ASX:PLS)
Pilbara Minerals Ltd, a prominent player in the lithium sector, has seen its share price hover approximately 10.2% above its 52-week low. As a leading ASX-listed lithium company, Pilbara Minerals owns 100% of the Pilgangoora Lithium Operation, the world’s largest independent hard-rock lithium operation, which it acquired in 2014.
The company specializes in the extraction and sale of spodumene concentrate, a key source of lithium. Pilbara Minerals sells its concentrate through long-term offtake agreements and spot sales on the Battery Material Exchange (BMX) platform. Notable offtake partners include Great Wall, a major Chinese automotive manufacturer, and POSCO, a South Korean steel producer.
The demand for lithium has surged due to its critical role in electric vehicle batteries and renewable energy technologies. This strong demand positions Pilbara as a significant player in the green technology sector. However, as with any commodities producer, Pilbara Minerals' revenue is subject to fluctuations in the global price of spodumene.
For those considering the investment potential of ResMed CDI, examining its valuation through a price-to-sales ratio can be insightful. Currently, ResMed shares have a price-to-sales ratio of 4.84x, which is below its five-year average of 6.13x. This indicates that the shares are trading at a lower valuation compared to their historical average. However, it is essential to consider multiple valuation metrics and broader context before making any investment decisions.
Both ResMed CDI and Pilbara Minerals Ltd continue to be key players in their respective sectors, with significant factors influencing their share prices and investment potential. As always, investors should conduct thorough research and consider various aspects before making investment choices.
